All short peptides presented on the cell surface by HLA-I and II molecules for detection and recognition by T cells are called Immunopeptidome. Immunopeptomic analysis aimed at studying the kinetics and composition of type I and type II immune peptides. In-depth characterization of immunopeptidomics can be applied to the development of new therapies for cancer, immune disorders, and infectious diseases.

Immunopeptidome Analysis Services

Characterizing immune peptides can help us discover targets for personalized cancer immunotherapy, such as neoantigens or tumor-associated antigens derived from tumor-specific mutations. In addition, new mRNA and peptide-based vaccines and cell-based therapeutics could be developed.

Alfa Oncology' high-precision mass spectrometry-based immunopeptidomics analysis includes our proprietary, highly sensitive immunopeptide enrichment and identification scheme. We can help you identify and identify more than 10,000 type I peptides and more than 10,000 type II peptides. Perform immunopeptidomic analysis with our optimized high-throughput immunopeptidomic analysis platform, which enables reproducible identification and quantification from the smallest sample material.

Based on our immunopeptidomics analysis platform, we can perform immunopeptidomics analysis, provide a list of all identified immunopeptides, and immunopeptidomic data quality analysis, such as data reporting.

Fig.1 Service flow for the immunopeptidome analysis.